FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007495000> ?p ?o ?g. }

• W2007495000 endingPage "990" @default.
• W2007495000 startingPage "982" @default.
• W2007495000 abstract "Soluble amyloid beta (Aβ) oligomers are widely accepted to be neurotoxic and lead to the memory loss and neuronal death observed in Alzheimer's disease (AD). Ample evidence suggests that impairment in glutamatergic signalling is associated with AD pathology. In particular, Aβ(1-42) is thought to affect N-methyl-d-aspartate (NMDA) receptor function and abolish the induction of long-term potentiation (LTP), which is regarded to be a phenomenon relevant to memory formation. The involvement of glutamatergic signalling in the pathology of AD is underscored by the therapeutic success of memantine, an uncompetitive NMDA receptor antagonist, used to treat patients with moderate to severe AD. In this study we show that Aβ(1-42) oligomers applied to acute murine hippocampal slices prevented, in a concentration-dependent manner, the development of CA1-LTP after tetanic stimulation of the Schaffer collaterals with a half maximal inhibitory concentration of around 2 nM (before oligomerization). The highest concentration of Aβ(1-42) oligomers (50 nM before oligomerization) completely blocked LTP (105 ± 1% potentiation versus 141 ± 3% in control) whereas scrambled Aβ(1-42) (50 nM) was without effect (144 ± 10% potentiation). Pre-incubation with memantine (1 μM) restored LTP in the presence of Aβ(1-42) (50 nM; 135 ± 5% potentiation). NMDA receptors containing the NR2B subunit have been proposed to play a particularly important role in excitotoxicity, functioning as extracellular death receptors. The metabotropic glutamate receptor 5 (mGluR5) is mechanistically coupled to postsynaptic NMDA receptors. As such, allosteric sites on both receptors offer alternative means to modulate NMDA receptor function. We therefore tested low concentrations (each 300 nM) of allosteric antagonists of NR2B (Ro 25-6981, [R-(R∗,S∗)]-α-(4-Hydroxyphenyl)-β-methyl-4(phenylmethyl)-1-piperidine propanol hydrochloride) and mGluR5 receptors (MPEP, 2-methyl-6-(phenylethynyl)-pyridine). Both compounds restored LTP in the presence of Aβ(1-42) oligomers (50 nM, fEPSPs were potentiated to 129 ± 13% and 133 ± 7% respectively). Finally, we demonstrated that slices from mice heterozygous for NR2B receptor) in the forebrain are not susceptible to the toxic effects of Aβ(1-42) oligomers but express normal LTP (138 ± 6%). These experiments demonstrate that glutamate receptor antagonists delivered at concentrations which still allow physiological activities in vitro, are able to prevent Aβ(1-42) oligomer-induced synaptic toxicity and further support the glutamatergic system as a target for the development of improved symptomatic/neuroprotective treatments for AD." @default.
• W2007495000 created "2016-06-24" @default.
• W2007495000 creator A5040327453 @default.
• W2007495000 creator A5057517491 @default.
• W2007495000 creator A5062163912 @default.
• W2007495000 creator A5071702581 @default.
• W2007495000 creator A5087077940 @default.
• W2007495000 date "2011-05-01" @default.
• W2007495000 modified "2023-09-27" @default.
• W2007495000 title "Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices" @default.
• W2007495000 cites W1557451274 @default.
• W2007495000 cites W1595726542 @default.
• W2007495000 cites W1637989849 @default.
• W2007495000 cites W1876061808 @default.
• W2007495000 cites W1960543132 @default.
• W2007495000 cites W1964673167 @default.
• W2007495000 cites W1967464880 @default.
• W2007495000 cites W1968024448 @default.
• W2007495000 cites W1970231358 @default.
• W2007495000 cites W1977823998 @default.
• W2007495000 cites W1980340730 @default.
• W2007495000 cites W1981570625 @default.
• W2007495000 cites W1988718039 @default.
• W2007495000 cites W1991988242 @default.
• W2007495000 cites W1993465897 @default.
• W2007495000 cites W1995683118 @default.
• W2007495000 cites W1999548133 @default.
• W2007495000 cites W2001900724 @default.
• W2007495000 cites W2003655335 @default.
• W2007495000 cites W2018213389 @default.
• W2007495000 cites W2019110724 @default.
• W2007495000 cites W2033554275 @default.
• W2007495000 cites W2037257064 @default.
• W2007495000 cites W2048661219 @default.
• W2007495000 cites W2050066016 @default.
• W2007495000 cites W2054628503 @default.
• W2007495000 cites W2068273333 @default.
• W2007495000 cites W2069312841 @default.
• W2007495000 cites W2078917784 @default.
• W2007495000 cites W2079912519 @default.
• W2007495000 cites W2081070804 @default.
• W2007495000 cites W2081605808 @default.
• W2007495000 cites W2081772055 @default.
• W2007495000 cites W2082151254 @default.
• W2007495000 cites W2096410114 @default.
• W2007495000 cites W2096557110 @default.
• W2007495000 cites W2103477251 @default.
• W2007495000 cites W2109171315 @default.
• W2007495000 cites W2113476104 @default.
• W2007495000 cites W2114163624 @default.
• W2007495000 cites W2115826405 @default.
• W2007495000 cites W2121504583 @default.
• W2007495000 cites W2126958454 @default.
• W2007495000 cites W2132844263 @default.
• W2007495000 cites W2147654688 @default.
• W2007495000 cites W2149247762 @default.
• W2007495000 cites W2150914528 @default.
• W2007495000 cites W2150999725 @default.
• W2007495000 cites W2154142567 @default.
• W2007495000 cites W2155580811 @default.
• W2007495000 cites W2162807572 @default.
• W2007495000 cites W2163401269 @default.
• W2007495000 cites W2165021720 @default.
• W2007495000 cites W586459384 @default.
• W2007495000 cites W81005182 @default.
• W2007495000 cites W1963638095 @default.
• W2007495000 doi "https://doi.org/10.1016/j.neuropharm.2011.01.051" @default.
• W2007495000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21310164" @default.
• W2007495000 hasPublicationYear "2011" @default.
• W2007495000 type Work @default.
• W2007495000 sameAs 2007495000 @default.
• W2007495000 citedByCount "137" @default.
• W2007495000 countsByYear W20074950002012 @default.
• W2007495000 countsByYear W20074950002013 @default.
• W2007495000 countsByYear W20074950002014 @default.
• W2007495000 countsByYear W20074950002015 @default.
• W2007495000 countsByYear W20074950002016 @default.
• W2007495000 countsByYear W20074950002017 @default.
• W2007495000 countsByYear W20074950002018 @default.
• W2007495000 countsByYear W20074950002019 @default.
• W2007495000 countsByYear W20074950002020 @default.
• W2007495000 countsByYear W20074950002021 @default.
• W2007495000 countsByYear W20074950002022 @default.
• W2007495000 countsByYear W20074950002023 @default.
• W2007495000 crossrefType "journal-article" @default.
• W2007495000 hasAuthorship W2007495000A5040327453 @default.
• W2007495000 hasAuthorship W2007495000A5057517491 @default.
• W2007495000 hasAuthorship W2007495000A5062163912 @default.
• W2007495000 hasAuthorship W2007495000A5071702581 @default.
• W2007495000 hasAuthorship W2007495000A5087077940 @default.
• W2007495000 hasConcept C160268369 @default.
• W2007495000 hasConcept C169760540 @default.
• W2007495000 hasConcept C170493617 @default.
• W2007495000 hasConcept C185592680 @default.
• W2007495000 hasConcept C197341189 @default.
• W2007495000 hasConcept C25274449 @default.
• W2007495000 hasConcept C26702167 @default.
• W2007495000 hasConcept C2776328245 @default.

• next